Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) reported full year 2025 revenue of $17.5 million, up 16% from 2024, driven by sleep testing services and the June 2025 acquisition of The Sleep Center of Nevada (SCN). Gross profit rose to $10.5 million with a 60% gross margin. Operating loss widened to $19.9 million on higher operating expenses of $30.4 million. Cash was $2.0 million at year-end, later supplemented by $6.8 million in post-year financings. Management cited a strategic pivot to acquisitions and alliances and will host a conference call on April 15, 2026.
Vivos Therapeutics (NASDAQ: VVOS) will release its full year 2025 financial results after market close on April 15, 2026 and hold a conference call the same day at 5:00 pm ET.
Management will review results, discuss strategic collaborations, and provide operational updates. A live webcast and a replay (passcode 1153783) will be available; the replay is accessible until April 29, 2026 and the webcast archive for 30 days.
Vivos Therapeutics (NASDAQ: VVOS) closed a private placement with New Seneca affiliate V-Co 3, raising $2.25 million (includes conversion of a prior $1.4 million bridge note) on March 31, 2026. Vivos issued common stock, a pre-funded warrant, and 2- and 5-year warrants exercisable at $1.09.
V-Co 3 paid $1.34 per share/warrant; aggregate Seneca investments since 2024 total $13.4 million. Vivos recorded an original issue discount of $140,000 and intends to use net proceeds for general working capital while pursuing its medical affiliation model and breakeven cash flow goal by end of 2026.
Vivos Therapeutics (NASDAQ: VVOS) announced that physician-owned practices supported by its Nevada management services subsidiary have received in-network status with multiple commercial insurers and participating status with Medicare in Las Vegas. The company also initiated legacy cost reductions, estimating approximately $4.0 million in annualized expense savings to lower cash burn and support a goal of becoming cash flow positive in fiscal 2026.
Vivos said the insurer network expansion should materially increase patient access and management services revenue, while workforce and vendor changes relate to shifting from a dental distribution model to a medical affiliation model.
Vivos Therapeutics (NASDAQ: VVOS) highlighted a peer-reviewed study linking narrower maxillary intermolar distance and higher palatal height to greater obstructive sleep apnea (OSA) severity, reporting a strong association (p<0.001) across 100 patients.
The company noted its FDA 510(k) clearance in November 2024 for Vivos CARE devices to treat severe OSA, U.S. clearance for adults and children, and asserted many patients finish treatment in under 12 months, often reducing the need for nightly CPAP or other lifetime interventions.
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with SoundHealth to distribute SoundHealth’s FDA-cleared Sonu® Band and new Spatial Sleep™ band across Vivos’ clinical network. Vivos will resell the devices and gain access to SoundHealth’s CT-accurate smartphone facial scanning and voice biomarker technology to aid screening, treatment, and monitoring of airway and sleep disorders.
The partnership leverages Vivos’ network of over 2,000 Vivos-trained dentists and sleep providers and aims to expand access to personalized, non-drug airway and sleep therapies.
Vivos Therapeutics (Nasdaq: VVOS) closed the exercise of outstanding warrants and received approximately $4.64 million in gross proceeds on January 20, 2026. The exercised warrants covered an aggregate of 1,982,356 originally issued in 2023–2024 at reduced exercise prices of $2.34 per share. As consideration, the company issued private new unregistered warrants to purchase 3,964,712 shares at $2.09 per share with staggered expirations (24 months and five years). Shares issuable on the exercised warrants are registered on Form S-3; new warrants were offered via an exemption and resale registration will be filed. Proceeds are intended for working capital and general corporate purposes.
Vivos Therapeutics (Nasdaq: VVOS) announced a definitive agreement for immediate exercise of outstanding warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices of $3.83–$5.05. The shares issuable upon exercise are registered for resale on Form S-3. Gross proceeds to the company are expected to be approximately $4.64 million before placement agent fees and offering expenses. The company will issue private, unregistered new warrants to purchase up to 3,964,712 shares at $2.09 per share; portions expire in 24 months and five years. The offering is expected to close on or about January 20, 2026, and net proceeds will be used for working capital and general corporate purposes.
Vivos Therapeutics (NASDAQ: VVOS) opened an affiliated sleep testing and treatment center in Auburn Hills, Michigan on Dec. 16, 2025, expanding its commercial affiliation model beyond Las Vegas.
The center operates under a July agreement with MISleep Solutions, where Vivos built out the facility, staffed and trained personnel, and will provide its FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea (OSA). Vivos positions the affiliation model as capital-efficient versus outright acquisitions while preserving accretive economics and expects to pursue similar partnerships nationwide.
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will join a Water Tower Research fireside chat on December 16, 2025 at 11:00 am ET.
Management will discuss the company’s strategic business model pivot, operational execution, the market opportunity and competitive environment for sleep-related breathing disorder treatments, and Vivos’ growth and financial strategies. The event is listen-only and requires registration. A replay will be available for 30 days in the Investor Relations section at vivos.com.